Controlled-release delivery of L-dopa associated with nonfatal hyperthermia, rigidity, and autonomic dysfunction.
Cunningham
M A
MA
Department of Neurology, Austin Hospital, Heidelberg, Victoria, Australia.
Darby
D G
DG
Donnan
G A
GA
D000328:Adult; D001342:Autonomic Nervous System Diseases / Q000139:chemically induced*; D001545:Benserazide / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009127:Muscle Rigidity / Q000139:chemically induced*; D010300:Parkinson Disease / Q000188:drug therapy
D003692:Delayed-Action Preparations; D004338:Drug Combinations; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide